[Correspondence] Clinical benefits of evolocumab appear less than hoped – Authors' reply

Our analysis1 of the association between LDL-cholesterol concentrations at 4 weeks and cardiovascular outcomes reported in FOURIER2 complemented the primary data from the randomised comparison between evolocumab and placebo. Unlike previous epidemiological studies and the selected studies cited by Simon B Dimmitt and colleagues, we analysed the association between the reduction of LDL-cholesterol concentrations to unprecedented low levels and clinical outcomes, adjusting for differences in baseline characteristics.

Source: LANCET - March 9, 2018 Category: General Medicine Authors: Robert P Giugliano, Anthony C Keech, Peter S Sever, Terje R Pedersen, Marc S Sabatine Tags: Correspondence Source Type: research